Abbott Laboratories $ABT Stock Purchased by Moody National Bank Trust Division

Moody National Bank Trust Division increased its stake in Abbott Laboratories (NYSE:ABT) by 35.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,659 shares of the healthcare product maker’s stock after purchasing an additional 5,387 shares during the quarter. Moody National Bank Trust Division’s holdings in Abbott Laboratories were worth $2,042,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Copley Financial Group Inc. lifted its holdings in shares of Abbott Laboratories by 2.1% during the 4th quarter. Copley Financial Group Inc. now owns 4,435 shares of the healthcare product maker’s stock valued at $556,000 after buying an additional 93 shares during the period. WealthTrust Axiom LLC increased its position in Abbott Laboratories by 3.2% during the fourth quarter. WealthTrust Axiom LLC now owns 3,064 shares of the healthcare product maker’s stock valued at $384,000 after acquiring an additional 94 shares during the last quarter. St. Johns Investment Management Company LLC increased its position in Abbott Laboratories by 1.0% during the second quarter. St. Johns Investment Management Company LLC now owns 9,859 shares of the healthcare product maker’s stock valued at $895,000 after acquiring an additional 101 shares during the last quarter. Davidson Investment Advisors lifted its holdings in Abbott Laboratories by 3.6% in the second quarter. Davidson Investment Advisors now owns 3,084 shares of the healthcare product maker’s stock valued at $280,000 after acquiring an additional 106 shares during the period. Finally, Kinloch Capital LLC boosted its position in Abbott Laboratories by 0.4% in the fourth quarter. Kinloch Capital LLC now owns 29,202 shares of the healthcare product maker’s stock worth $3,659,000 after purchasing an additional 111 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. JPMorgan Chase & Co. upped their price target on shares of Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Robert W. Baird initiated coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 target price for the company. Weiss Ratings raised shares of Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, September 18th. TD Cowen reiterated a “buy” rating and issued a $135.00 price target on shares of Abbott Laboratories in a research report on Tuesday, September 8th. Finally, Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target on the stock in a research note on Thursday, August 13th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $119.80.

Abbott Laboratories Stock Performance

NYSE ABT traded down $1.96 on Tuesday, reaching $98.14. 10,575,706 shares of the stock were exchanged, compared to its average volume of 11,348,987. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a one year low of $81.97 and a one year high of $135.13. The firm has a market capitalization of $169.82 billion, a PE ratio of 31.76, a PEG ratio of 1.81 and a beta of 0.59. The company’s 50-day simple moving average is $106.89 and its two-hundred day simple moving average is $98.52.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company’s revenue was up 13.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts expect that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.